sb 202190 has been researched along with Angiogenesis, Pathologic in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, XJ | 1 |
| Chen, GL | 1 |
| Yu, SC | 1 |
| Xu, C | 1 |
| Xin, YH | 1 |
| Li, TT | 1 |
| Shi, Y | 1 |
| Gu, A | 1 |
| Duan, JJ | 1 |
| Qian, C | 1 |
| Cui, YH | 1 |
| Zhang, X | 1 |
| Bian, XW | 1 |
1 other study available for sb 202190 and Angiogenesis, Pathologic
| Article | Year |
|---|---|
TGF-β1 enhances tumor-induced angiogenesis via JNK pathway and macrophage infiltration in an improved zebrafish embryo/xenograft glioma model.
Topics: Angiogenesis Inhibitors; Animals; Animals, Genetically Modified; Anthracenes; Cell Line, Tumor; Cell | 2013 |